Price
CHART BY
Frequently asked questions
What is Collegium Pharm's market capitalization?
The market capitalization of Collegium Pharm is $766.03M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Collegium Pharm's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Collegium Pharm is 19.06. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Collegium Pharm?
Collegium Pharm's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.234. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Collegium Pharm's stock?
Currently, 5 analysts cover Collegium Pharm's stock, with a consensus target price of $49.60. Analyst ratings provide insights into the stock's expected performance.
What is Collegium Pharm's revenue over the trailing twelve months?
Over the trailing twelve months, Collegium Pharm reported a revenue of $808.21M.
What is the EBITDA for Collegium Pharm?
Collegium Pharm's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $396.21M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Collegium Pharm?
Collegium Pharm has a free cash flow of $328.28M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Collegium Pharm have, and what sector and industry does it belong to?
Collegium Pharm employs approximately 423 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Collegium Pharm's shares?
The free float of Collegium Pharm is 31.84M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $766.03M
- EPS (TTM)
- $1.234
- Free Float
- 31.84M
- P/E ratio (TTM)
- 19.06
- Revenue (TTM)
- $808.21M
- EBITDA (TTM)
- $396.21M
- Free Cashflow (TTM)
- $328.28M
Pricing
- 1D span
- $23.34$24.29
- 52W span
- $23.43$50.00
Analyst Ratings
The price target is $49.60 and the stock is covered by 5 analysts.
Buy
4
Hold
1
Sell
0
Information
Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
- Employees
- 423
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- COLL
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet